CN114558000B - Application of sesamin in preparation of medicine for treating melanoma - Google Patents
Application of sesamin in preparation of medicine for treating melanoma Download PDFInfo
- Publication number
- CN114558000B CN114558000B CN202210436307.0A CN202210436307A CN114558000B CN 114558000 B CN114558000 B CN 114558000B CN 202210436307 A CN202210436307 A CN 202210436307A CN 114558000 B CN114558000 B CN 114558000B
- Authority
- CN
- China
- Prior art keywords
- melanoma
- tumor
- medicine
- cells
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of praeruptorin in preparing a medicine for treating melanoma. The invention discloses the effect of the white flower falcarind in the aspect of treating melanoma, and experimental results show that the white flower falcarind has obvious anti-tumor effect on in-vivo melanoma cells, can effectively enhance the activities of cytokines and NK cells in serum of tumor-bearing mice, and indicate that the anti-tumor effect can be related to enhancing immunity. Can be used for preparing anti-melanoma medicine.
Description
Technical Field
The invention relates to the field of medicines, in particular to an application of praeruptorin in preparation of a medicine for treating melanoma.
Background
Human melanoma, particularly malignant melanoma, is a highly metastatic tumor that is markedly resistant to chemotherapy. After decades of treatment and research, the survival rate of melanoma patients is 3% -5%, especially in adult primary tumors, increases more rapidly. Therefore, searching for high-efficiency low-toxicity traditional Chinese medicines to change the biological behaviors of tumors has become an important strategy for tumor treatment.
Peucedanin (Praerupterin B, CAS number 81740-07-0; molecular formula C) 24 H 26 O 7 The method comprises the steps of carrying out a first treatment on the surface of the Molecular weight: 426.46 Is an angular pyranocoumarin component extracted from radix Peucedani, and has effects of reducing qi phlegm, dispelling pathogenic wind and clearing heat. In recent years, it has been found that the compounds can improve diet-induced hyperlipidemia and alleviate insulin resistance by modulating SREBP signaling pathways. However, no report on the treatment of melanoma by the compound is currently available.
Disclosure of Invention
The invention provides a method for filling the blank of the prior art, firstly discloses the pharmaceutical activity of the praeruptorin in treating melanoma, and provides the following technical scheme:
in a first aspect of the invention, there is provided the use of peucedanum praeruptorum as active ingredient in the manufacture of a medicament for the treatment of melanoma.
In one embodiment, the use comprises inhibiting melanoma growth.
In one embodiment, the use includes increasing IFN-gamma expression levels and decreasing IL-4 secretion levels in serum.
In one embodiment, the use comprises enhancing NK cell killing activity in vivo.
In one embodiment, the medicament is a compound preparation prepared by compounding the peucedanum praeruptorum and auxiliary materials conventional in the art.
In one embodiment, the compound preparation is in the form of a tablet, granule, pill, capsule or injection.
Detailed Description
The following description of the preferred embodiments of the present invention is provided for the purpose of illustration and explanation only and is not intended to limit the present invention.
EXAMPLE 1 tumor-inhibiting effect of Peucedanin
1. Experimental materials: the praeruptorin (hereinafter referred to as PB) is purchased from the biological technology Co., ltd. Of Dou Geli (purity not less than 98%); thiazole blue (MTT) was purchased from Amersco, USA, RPMI1640 medium, trypsin, fetal bovine serum was purchased from Gibco, USA, and mouse IFN-gamma and IL-4 detection kits were purchased from Nanjing Diels Biotechnology Co.
2. Experimental cells and animals:
human melanoma a375 cell line was purchased from Shanghai Bomaide biotechnology Co., ltd; BALB/c mice, 18-20g in weight, were purchased from Peking Vitre Liwa laboratory animal technologies Co.
3. The experimental method and the grouping are as follows:
after the A375 cells growing in logarithmic phase are digested with pancreatin, the cells are centrifuged to prepare a cell suspension, and the right side of the mice is inoculated with about 2X 10 injections 5 Cells/cells. After 3 weeks, mice with successfully modeled transplants (diameter not less than 5 mm) were screened, and the transplants were further divided into 5 groups, i.e., physiological saline group (0.9% sodium chloride injection, NS control group), acacia control group (5% acacia aqueous solution), PB low dose group (5 mg/(kg·d)), PB medium dose group (10 mg/(kg·d)) and PB high dose group (20 mg/(kg·d)), 10 per group, by adopting a random number table method. PB and acacia were suspended, and each mouse was perfused with either PB or NS at 0.5ml/d for 28d (culling if tumor length > 17 mm), then the mice were sacrificed and the tumor mass was weighed and tumor inhibition was calculated (tumor growth inhibition rate, TGI).
TGI calculation formula:
TGI (%) = (average mass of experimental control group graft versus average mass of experimental group graft)/average mass of experimental control group graft x 100%
Statistical methods: all data are analyzed by adopting SPSS 17.0 statistical software, metering data are expressed by mean ± standard deviation, single-factor analysis of variance is carried out among groups, and P < 0.05 is taken as a difference to have statistical significance.
4. Experimental results:
compared with normal mice, the food intake and water intake of tumor-bearing mice are reduced, the hair color becomes dry and yellow, and the hair is partially dehaired and has poor mental condition. After 28d of administration, the PB treated mice had improved mental status and gradually restored their hair gloss, with an increase in dietary intake. As shown in Table 1, the difference in mass of mice in each of the groups of the transplanted tumor models before administration was not statistically significant, and P was > 0.05. Mice became lighter in body mass after PB treatment, with differences statistically significant, p=0.05, relative to NS control; wherein the mass of the medium dose group body is reduced to the minimum, and P is less than 0.01. The cytoma mass is compared, and compared with an NS control group, the difference of each experimental group has statistical significance, and P is less than 0.05; wherein the difference is most pronounced in the high dose group, P < 0.01.
Table 1 PB effect on mouse body weight and tumor mass (n=10)
Note that: compared with the NS control group, the P is less than 0.05, and the #P is less than 0.01
EXAMPLE 2 Effect of Peucedanin on mouse IFN-gamma and IL-4 secretion levels
ELISA method for detecting IFN-gamma and IL-4 expression in serum
The procedure is described in detail with reference to IFN-gamma and IL-4 detection kits: taking a kit and standing at room temperature, coating a plate with a negative control hole, 8 standard substance holes (2000, 1000, 500, 250, 125, 62.5, 31.25 and 15.625 ng/L) with different concentrations for detecting IFN-gamma, 8 standard substance holes (500, 250, 125, 62.5, 31.25 and 15.625, 7.8125 and 3.91 pg/L) with different concentrations for detecting IL-4, directly adding 50 mu L of sample diluent into the negative hole, and adding 40 mu L of sample diluent into the rest holes and 10 mu L of sample; incubating for 60min at 37deg.C with sealing plate membrane, discarding supernatant, washing, repeating for 5 times, and drying; adding 50 mu L of enzyme-labeled reagent into each hole, continuously incubating for 40min, discarding supernatant, washing with washing solution for 5 times, and drying; 50 mu L of each of the color developing agents A and B is respectively added into each hole, and the mixture is gently mixed, and the color is developed for 10min at 37 ℃ in a dark place; the color development was stopped by adding 50. Mu.L of stop solution to each well. Absorbance (a value) of each well was measured at a wavelength of a blank Kong Diaoling, 450nm and a corresponding concentration value was calculated.
2. Experimental results
As shown in Table 2, PB enhances IFN-gamma expression level in serum of experimental mice, and compared with NS control group, the difference of each group of PB experiment has statistical significance, and P is less than 0.05; wherein, the secretion level of the high-dose group is highest and reaches 721.98 +/-12.47 ng/L, and P is less than 0.01. While the bleeding level of IL-4 in each group is reduced by PB treatment, the reduction of the high-dose group is most obvious, and the dosage reaches 120.68 +/-5.26 ng/L and P is less than 0.05.
Table 2 PB effect on IFN-. Gamma.and IL-4 expression in serum of tumor-bearing mice (n=10)
Note that: compared with the NS control group, the P is less than 0.05, and the #P is less than 0.01
EXAMPLE 3 Effect of Peucedanin on NK cell killing Activity of transplanted tumor mice
Determination of NK cell killing Activity of mice by MTT method
1.1 preparation of potent and target cells mice were taken from spleen and inguinal lymph nodes and made into lymphocyte suspensions using RP containing 10% calf serum as effector cellsMI1640 culture medium was adjusted to 1X 10 cell concentration 6 mL -1 、5×10 5 mL -1 And 2X 10 5 mL -1 . The target cells are YAC-1 cells, and the cell concentration is adjusted to be 1 multiplied by 10 4 mL -1 。
1.2 NK cell killing activity assay in 96 well plates, assay Kong Jiaxiao, 50. Mu.L each of target cells; effector control wells plus 50 μl of effector and 1640 medium each; target cells Kong Jiaba and 1640 were each 50. Mu.L in culture. 3 compound wells are made for each specimen, and the effective target ratios are 100:1, 50:1 and 20:1 respectively. Placing the culture plate into CO 2 Culturing in an incubator for 20h, and adding 20 mu L of 5mg/ml MTT into each well for further incubation for 4h; after completion, 150. Mu.L of dimethyl sulfoxide (DMSO) was added to each well to dissolve the precipitate, and the mixture was subjected to shaking by a micro-oscillator for 10 minutes, and absorbance (A value) of each well was measured at a wavelength of 490nm on an microplate reader.
Killing activity (%) = (1- (experimental group mean a value-effector group mean a value)/target cell group mean a value) ×100%
2. Experimental results
As shown in Table 3, PB can enhance the killing activity of NK cells of mice, the increase of the killing activity of NK cells is obvious when the effective target ratio is 50:1, the killing activity of NK cells of each treatment group of PB is higher than that of an NS control group, the difference is statistically significant, and P is less than 0.05; and the NK cell activity of the high-dose group reaches 50.32%, the increase is most obvious, and P is less than 0.01.
Table 3 PB effect on NK cell activity of tumor-bearing mice (n=10)
Note that: compared with the NS control group, the P is less than 0.05, and the #P is less than 0.01
It will be apparent to those skilled in the art that various modifications and variations can be made to the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention also include such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.
Claims (3)
1. Application of sesamin as active ingredient in preparing medicine for treating melanoma is provided.
2. The use according to claim 1, wherein the medicament is a pharmaceutical formulation of praeruptorin in combination with adjuvants conventional in the art.
3. The use according to claim 2, wherein the pharmaceutical formulation is in the form of a tablet, granule, pill, capsule or injection.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210436307.0A CN114558000B (en) | 2022-04-24 | 2022-04-24 | Application of sesamin in preparation of medicine for treating melanoma |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210436307.0A CN114558000B (en) | 2022-04-24 | 2022-04-24 | Application of sesamin in preparation of medicine for treating melanoma |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114558000A CN114558000A (en) | 2022-05-31 |
CN114558000B true CN114558000B (en) | 2023-08-11 |
Family
ID=81721429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210436307.0A Active CN114558000B (en) | 2022-04-24 | 2022-04-24 | Application of sesamin in preparation of medicine for treating melanoma |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114558000B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1433790A (en) * | 2002-01-21 | 2003-08-06 | 方宏勋 | Use of Chinese herb peucedanum praeruptorum in preparation of medicine for treating tumor |
-
2022
- 2022-04-24 CN CN202210436307.0A patent/CN114558000B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1433790A (en) * | 2002-01-21 | 2003-08-06 | 方宏勋 | Use of Chinese herb peucedanum praeruptorum in preparation of medicine for treating tumor |
Non-Patent Citations (1)
Title |
---|
前胡化学成分及药理作用的研究进展;吴霞;毕赢;王一涛;;食品与药品(第11期);442-445 * |
Also Published As
Publication number | Publication date |
---|---|
CN114558000A (en) | 2022-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021014112A2 (en) | USES OF DON PRO-DRUG COMPOUND AND IMMUNE CONTROL POINT INHIBITOR TO TREAT CANCER, AS WELL AS COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
CN107050430A (en) | Reverse the immunosuppressive method of Langerhans cell | |
CN108283643A (en) | A kind of thiazadione class compound prepare prevent or the drug for the treatment of rheumatoid arthritis in application | |
CN114558000B (en) | Application of sesamin in preparation of medicine for treating melanoma | |
CN102688493A (en) | Pharmaceutical composition containing resveratrol, resveratrol derivative and Bc1-2 inhibitor, and application thereof | |
CN109419803A (en) | Cell autophagy inhibitor and Afatinib pharmaceutical composition and its purposes in preparation tumour Synergistic preparations | |
US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
CN109010333A (en) | Dehydrogenation curvularin is inhibiting the application in Hedgehog access | |
CN108653293B (en) | Application of JAK2 inhibitor in preventing and treating signet ring cell carcinoma | |
US20070207198A1 (en) | Use Of N-Acety1-D-Glucosamine In The Manufacture Of Medicaments For Anti-Tumors And Anti-Metastasis | |
CN106668061B (en) | A kind of anticancer pharmaceutical composition containing cis-platinum | |
CN111848747B (en) | Polypeptide for preventing and/or treating malignant tumor, application and medicament | |
CN117866069B (en) | Iodine-131 marked small molecule polypeptide TFMP-Y4 and preparation method and application thereof | |
CN115990162B (en) | Application of 4-hydroxy-2-pyridone alkaloid in preparation of medicines for treating gastric cancer | |
CN114748630B (en) | Platinum anti-cancer medicine composition with improving effect and application thereof | |
CN112386600B (en) | Application of Hupeimine in preparation of medicine for preventing acute kidney injury | |
CN118059108B (en) | Pharmaceutical composition and application thereof in preparation of antitumor drugs | |
CN114224893B (en) | Application of quinazoline derivative in preparation of drugs for preventing and treating arsenic-induced liver injury | |
CN108992463A (en) | A kind of composition and pharmaceutical preparation for treating lung cancer | |
TWI804333B (en) | Use of medicinal composition for treating lung cancer | |
CN111728960B (en) | Application of bisoprolol fumarate and docetaxel in preparation of antitumor drugs | |
CN109602737B (en) | Application of hydroxysafflor yellow B in preparation of medicine for treating gastric cancer and medicine | |
CN114222580B (en) | Polypeptide medicine for preventing and/or treating ovarian cancer and application thereof | |
RU2234962C2 (en) | Method for treating the cases of non-resectable pancreatic carcinoma | |
CN107929344B (en) | Lithospermum compound composition for preventing and treating laryngeal cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |